Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
// Hui Xu 1 , Shervin Rahimpour 2 , Cody L. Nesvick 2 , Xu Zhang 1 , Jingyun Ma 1 , Min Zhang 1 , Ge Zhang 3 , Li Wang 1 , Chunzhang Yang 2 , Christopher S. Hong 2 , Anand V. Germanwala 4 , J. Bradley Elder 5 , Abhik Ray-Chaudhury 2 , Yu Yao 6 , Mark R. Gilbert 7 , Russell R. Lonser 5 , John D. Heiss 2 , Roscoe O. Brady 2 , Ying Mao 6 , Jianhua Qin 1 and Zhengping Zhuang 2 1 Division of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China 2 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA 3 Department of Immunology, Dalian Medical University, Dalian, China 4 Department of Neurological Surgery, Loyola University Medical Center, Chicago, Illinois, USA 5 Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA 6 Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China 7 Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence to: Ying Mao, email: // Jianhua Qin, email: // Zhengping Zhuang, email: // Keywords : glioblastoma, bevacizumab, epithelial-mesenchymal transition, pathologic angiogenesis, hypoxia-inducible factor Received : February 12, 2015 Accepted : February 19, 2015 Published : March 14, 2015 Abstract Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), can attenuate tumor-associated edema and improve patient symptoms but based on magnetic resonance imaging, is associated with non-enhancing tumor progression and possibly gliosarcoma differentiation. To gain insight into these findings, we investigated the role of hypoxia and epithelial-mesenchymal transition (EMT)-associated proteins in GBM. Tumor markers of hypoxia and EMT were upregulated in bevacizumab-treated tumors from GBM patients compared to untreated counterparts. Exposure of glioma cells to 1% oxygen tension increased cell proliferation, expression of EMT-associated proteins and enhanced cell migration in vitro . These phenotypic changes were significantly attenuated by pharmacologic knockdown of hypoxia-inducible Factor 1α (HIF1α) or HIF2α, indicating that HIFs represent a therapeutic target for mesenchymal GBM cells. These findings provide insights into potential development of novel therapeutic targeting of angiogenesis-specific pathways in GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · cited 4×
“In addition to enhancing their invasive capacity, EMT endows differentiated cancer cells with the capacity to become stem cells and provides a mechanism for their continued production [26, 27, 34, 35].”
BackgroundInfluentialModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354 · cited 1×
“Activation of the hypoxia signaling pathway is associated with increased activation of the EMT program, increased cell motility and adoption of stem-like traits and is thus an attractive therapeutic target for solid tumors [27, 35, 41, 42, 45-49].”
BackgroundDirect regulation of TWIST by HIF-1α promotes metastasis
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C., & Wu, K.-J. (2008) · Nature Cell Biology · doi:10.1038/ncb1691 · Cited by 1,345
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α
Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., Engh, J., Iwama, T., Kunisada, T., Kassam, A. B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.252 · Cited by 656
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 1×
“VEGF-resistant cancer cells also secrete significantly more IL-17, resulting in the recruitment of immature immune cells to the tumor microenvironment [37].”
BackgroundKrishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., & Semenza, G. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3719 · Cited by 415 · cited 3×
“This process is crucially dependent on HIF stabilization, as EMT in VHL-null renal cell carcinoma occurs in the absence of true hypoxia [41].”
Background
Cited by
Sørensen, M. D., Dahlrot, R. H., Boldt, H. B., Hansen, S., & Kristensen, B. W. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12428 · Cited by 273
Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment
Tsai, H.-F., Trubelja, A., Shen, A. Q., & Bao, G. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0137 · Cited by 214
A disease model of diabetic nephropathy in a glomerulus-on-a-chip microdevice
Wang, L., Tao, T., Su, W., Yu, H., Yu, Y., & Qin, J. (2017) · Lab on a Chip · doi:10.1039/c7lc00134g · Cited by 207
Self-citationTumor-on-a-chip for integrating a 3D tumor microenvironment: chemical and mechanical factors
Wan, L., Neumann, C. A., & LeDuc, P. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00550a · Cited by 120
Bernstock, J. D., Ye, D., Gessler, F. A., Lee, Y.-J., Peruzzotti-Jametti, L., Baumgarten, P., Johnson, K. R., Maric, D., Yang, W., Kögel, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07631-9 · Cited by 46
Metadata
- Authors
- Xu, H., Rahimpour, S., Nesvick, C. L., Zhang, X., Ma, J., Zhang, M., Zhang, G., Wang, L., Yang, C., Hong, C. S., Germanwala, A. V., Elder, J. B., Ray-Chaudhury, A., Yao, Y., Gilbert, M. R., Lonser, R. R., Heiss, J. D., Brady, R. O., Mao, Y., Qin, J., & Zhuang, Z.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-03-14
- Volume
- 6
- Issue
- 14
- Pages
- 11882-11893
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1536103630
- Cited by
- 91
- References
- 10
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.